Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQC3564 + montelukast sodium
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TQC3564 + montelukast sodium is a **fixed-dose combination drug** composed of TQC3564 and **montelukast sodium**. Montelukast sodium is a **leukotriene receptor antagonist** indicated for the treatment and prevention of asthma, allergic rhinitis, and prevention of exercise-induced bronchoconstriction[1][2][3][4][6]. Its mechanism of action is selective inhibition of the cysteinyl leukotriene receptor type 1 (CysLT1), blocking leukotriene D4-mediated effects such as bronchoconstriction, airway inflammation, and edema[1][4][6]. TQC3564's mechanism and pharmacological profile, as well as the specific indication and rational for the combination with montelukast, are not provided in current reference sources. The combination likely aims to provide synergistic or additive benefit for respiratory or inflammatory diseases, but details on the development stage, clinical data, or specific use remain unavailable.
- Other names
- TQC3564 + montelukast sodium
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)
Beyond the preview
Go deeper on TQC3564 + montelukast sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQC3564 + montelukast sodium.